Novo to acquire Ritedose from AGIC Capital and Humanwell.

Novo, a life science investor, agreed to acquire Ritedose, a sterile pharmaceutical manufacturer, from AGIC Capital, a European-Asian private equity firm, and Humanwell, a pharmaceutical company. Financial terms were not disclosed. "Ritedose is a mission-driven company helping bring life-saving drugs to market with the highest focus on quality and sterility. We look forward to partnering with Jody and the Ritedose team as they continue to deliver best-in-class quality solutions to the biopharmaceutical industry," Jonathan Levy, Novo Senior Partner.